| Original language | English |
|---|---|
| Pages (from-to) | 2429-2431 |
| Number of pages | 3 |
| Journal | Leukemia |
| Volume | 29 |
| Issue number | 12 |
| DOIs | |
| Publication status | Published - Dec 1 2015 |
ASJC Scopus subject areas
- Hematology
- Cancer Research
- Anesthesiology and Pain Medicine
Cite this
Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma. / Cavo, M.; Pantani, L.; Pezzi, A.; Petrucci, M. T.; Patriarca, F.; Di Raimondo, F.; Marzocchi, G.; Galli, M.; Montefusco, V.; Zamagni, E.; Gamberi, B.; Tacchetti, P.; Brioli, A.; Palumbo, A.; Sonneveld, P.
In: Leukemia, Vol. 29, No. 12, 01.12.2015, p. 2429-2431.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma
AU - Cavo, M.
AU - Pantani, L.
AU - Pezzi, A.
AU - Petrucci, M. T.
AU - Patriarca, F.
AU - Di Raimondo, F.
AU - Marzocchi, G.
AU - Galli, M.
AU - Montefusco, V.
AU - Zamagni, E.
AU - Gamberi, B.
AU - Tacchetti, P.
AU - Brioli, A.
AU - Palumbo, A.
AU - Sonneveld, P.
PY - 2015/12/1
Y1 - 2015/12/1
UR - http://www.scopus.com/inward/record.url?scp=84951567534&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84951567534&partnerID=8YFLogxK
U2 - 10.1038/leu.2015.274
DO - 10.1038/leu.2015.274
M3 - Article
C2 - 26442610
AN - SCOPUS:84951567534
VL - 29
SP - 2429
EP - 2431
JO - Leukemia
JF - Leukemia
SN - 0887-6924
IS - 12
ER -